Overview

Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Status:
Active, not recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This is an randomized, controlled, multicenter phase 3 clinical trial. The purpose of this study is to evaluate the efficacy and safety of single-agent capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC).

Phase:

Phase 3

Details

Lead Sponsor:

Sun Yat-sen University

Collaborators:

Air Force Military Medical University, China
Cancer Hospital of Guangxi Medical University
Cancer Hospital of Guizhou Province
Fifth Affiliated Hospital, Sun Yat-Sen University
First Affiliated Hospital of Zhejiang University
First People's Hospital of Foshan
Henan Cancer Hospital
Hunan Cancer Hospital
Jilin Provincial Tumor Hospital
Peking University
Second Affiliated Hospital of Soochow University
The First Affiliated Hospital of Guangdong Pharmaceutical University
The First Affiliated Hospital of Xiamen University
Tongji Hospital
West China Hospital
Wuhan Union Hospital, China
Xiangya Hospital of Central South University

Treatments:

Capecitabine